Suppr超能文献

头孢美唑(CS - 1170)在围产期孕妇中的安全性研究(作者译)

[A study of safety of cefmetazole (CS-1170) in pregnant women during the perinatal stage (author's transl)].

出版信息

Jpn J Antibiot. 1981 Jun;34(6):907-14.

PMID:6945451
Abstract

Cefmetazole has a high safety rating when used in perinatal stage chemotherapy and thus it is a very useful antibiotic. However, cefmetazole is not an antibiotic to be administered primarily as a preventive. It should be used mainly in treating other agents resistant Gram-negative bacilli infections. In doing so, cefmetazole will become highly useful. 2. The safe dose of cefmetazole (CMZ) to the mother in the perinatal period is 1 approximately equal to 2 g/day. The administration of 4 g/day in a severe case is not contraindicated. 2. The fetus showed no signs of distress or side effects from cefmetazole (CMZ) crossing the mother's placental barrier. The transition of cefmetazole (CMZ) into the mother's milk is insignificant quantitatively but remains unknown qualitatively.

摘要

头孢美唑在围产期化疗中使用时具有较高的安全评级,因此它是一种非常有用的抗生素。然而,头孢美唑并非主要作为预防性使用的抗生素。它应主要用于治疗其他耐药革兰氏阴性杆菌感染。这样,头孢美唑将变得非常有用。2. 围产期母亲使用头孢美唑(CMZ)的安全剂量约为1至2克/天。严重病例中每天使用4克并无禁忌。2. 胎儿未表现出因头孢美唑(CMZ)穿过母亲胎盘屏障而产生的窘迫或副作用迹象。头孢美唑(CMZ)向母乳中的转移在数量上微不足道,但在质量上仍不清楚。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验